Aarti Drugs Q3 FY23 revenue grows 4%
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Biocon Foundation has pioneered a mHealth-technology-based (mobile health) oral cancer screening program in India
Valentas and Arnipin are indicated to reduce repeated hospitalization and the risk of cardiovascular death among adult patients with chronic mild to moderate heart failure
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
In a time when conversations around mental health have become ever more urgent Vaidya’s work is extremely contextual
ANSSI Wellness launches Asia’s premier and USA-patented ‘Spinal Decompression Treatment’ center in Nashik
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
The company is one of the most profitable companies manufacturing speciality chemicals in India
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
The expansion in Indore is well-aligned with Lupin Diagnostics’ commitment to improving access to high-quality, reliable, and advanced testing centres and home collection facilities at an affordable price
Subscribe To Our Newsletter & Stay Updated